HomeCompareGBS vs EPRT

GBS vs EPRT: Dividend Comparison 2026

GBS yields 422.65% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBS wins by $17170.25M in total portfolio value
10 years
GBS
GBS
● Live price
422.65%
Share price
$0.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17170.31M
Annual income
$11,716,925,996.02
Full GBS calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — GBS vs EPRT

📍 GBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBSEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBS + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBS pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBS
Annual income on $10K today (after 15% tax)
$35,925.61/yr
After 10yr DRIP, annual income (after tax)
$9,959,387,096.62/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, GBS beats the other by $9,959,375,901.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBS + EPRT for your $10,000?

GBS: 50%EPRT: 50%
100% EPRT50/50100% GBS
Portfolio after 10yr
$8585.19M
Annual income
$5,858,469,583.44/yr
Blended yield
68.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

GBS
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-6.8
Piotroski
5/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBS buys
0
EPRT buys
0
No recent congressional trades found for GBS or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBSEPRT
Forward yield422.65%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$17170.31M$64.3K
Annual income after 10y$11,716,925,996.02$13,170.85
Total dividends collected$16675.91M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: GBS vs EPRT ($10,000, DRIP)

YearGBS PortfolioGBS Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$52,965$42,265.43$11,212$512.01+$41.8KGBS
2$265,889$209,215.55$12,689$692.09+$253.2KGBS
3$1,266,062$981,561.13$14,521$944.30+$1.25MGBS
4$5,722,749$4,368,062.66$16,841$1,302.88+$5.71MGBS
5$24,575,825$18,452,483.99$19,841$1,821.64+$24.56MGBS
6$100,354,560$74,058,426.77$23,818$2,587.47+$100.33MGBS
7$390,010,320$282,630,940.68$29,230$3,744.65+$389.98MGBS
8$1,443,848,768$1,026,537,725.78$36,816$5,540.38+$1443.81MGBS
9$5,096,622,021$3,551,703,839.84$47,806$8,413.17+$5096.57MGBS
10$17,170,311,559$11,716,925,996.02$64,324$13,170.85+$17170.25MGBS

GBS vs EPRT: Complete Analysis 2026

GBSStock

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Full GBS Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this GBS vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBS vs SCHDGBS vs JEPIGBS vs OGBS vs KOGBS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.